3/14/2014 7:04:19 AM
Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2013.
“We expect continued progress for Anacor in 2014, with the potential approval and commercial launch of our lead compound, tavaborole, and the initiation of Phase 3 clinical trials of AN2728 in mild-to-moderate atopic dermatitis patients.”
“2013 was a transformational year for Anacor, as we advanced our two late-stage programs and successfully resolved our arbitration with Valeant, which led to a significant cash settlement,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
comments powered by